aside-oc ASIDE Oncology 3069-9959 3069-9967 PubPorta Publishing LLC 10.71079/ASIDE.Onc.032526533 Review Article The Relationship Between pks⁺ Escherichia coli and Colorectal Cancer: A Review https://orcid.org/0009-0000-3057-1785 Ulziitsogt Bolor Project Administration Visualization Conceptualization https://orcid.org/0000-0002-7900-974X Batbold Chuluunbileg Methodology Writing – Original Draft https://orcid.org/0009-0006-9073-3524 Sumiyabazar Tsogdulam Visualization Writing – Original Draft https://orcid.org/0009-0005-5658-6762 Dashjamts Gantogtokh Resources https://orcid.org/0009-0000-1512-4055 Tsedendorj Yumchinsuren Data Curation https://orcid.org/0000-0001-9982-949X Badamjav Tegshjargal Writing – Review & Editing Supervision https://orcid.org/0000-0001-6314-6996 Dondov Ganchimeg Visualization Resources https://orcid.org/0000-0002-2565-0347 Lonjid Tulgaa Supervision https://orcid.org/0000-0003-3109-2166 Batsaikhan Batbold Project Administration Conceptualization Batbold.ims@mnums.edu.mn Department of Internal Medicine, Institute of Medical Sciences, Ministry of Economy and Development, Ulaanbaatar Mongolia Department of Oncology, Institute of Medical Sciences, Ministry of Economy and Development, Ulaanbaatar Mongolia Corresponding author. E-mail: Batbold.ims@mnums.edu.mn

The authors declare no conflicts of interest.

 25 03 2026 2026 1 2 1 11 22 01 2026 12 03 2026 14 03 2026 2026 Bolor Ulziitsogt, Chuluunbileg Batbold, Tsogdulam Sumiyabazar, Gantogtokh Dashjamts, Yumchinsuren Tsedendorj, Tegshjargal Badamjav, Ganchimeg Dondov, Tulgaa Lonjid, Batbold Batsaikhan This is an open-access article.

Introduction: According to GLOBOCAN estimates, colorectal cancer (CRC) was the third most common cancer worldwide in 2020, comprising 11% of all cancer diagnoses. Researchers’ interest in CRC development has shifted toward the gastrointestinal microbiome, especially the mutagenicity of pks⁺ E. coli. Therefore, we aimed to review the current evidence on the relationship between pks⁺ E. coli and CRC. Method: We reviewed the literature reporting the association between pks⁺ E. coli and CRC, which was obtained from three databases: PubMed, Google Scholar, and the Cochrane Library, published between January 2021 and January 2026. We used the following keywords for our search strategy: pks, Escherichia coli, and colorectal cancer. Result: As stated in the original studies, the contribution of pks⁺ E. coli to CRC development was associated with a higher prevalence in the CRC group than in the healthy group. However, these results are inconsistent across the studies.

Conclusion: Given the limited evidence, researchers should conduct larger cohort studies to clarify this relationship and identify other factors contributing to the presence of pks⁺ E. coli, particularly across diverse clinical settings. Furthermore, clinical translation, such as the utilization of screening or therapeutic biomarkers, requires prospective validation and standardized detection methods.

 Colibactin Colorectal cancer Microbiome PKS The authors did not receive any external funding for this study. Introduction

According to GLOBOCAN estimates provided by the International Agency for Research on Cancer (IARC), colorectal cancer (CRC) was the third most common cancer worldwide in 2020, comprising 11% of all cancer diagnoses [1,2]. In 2022, Asia accounted for 50.2% of global CRC cases, with 966.400 new cases and 462.000 deaths, which reflects the high incidence of the cancer in Asian countries [3]. Mongolia has relatively low CRC incidence and mortality rates compared with countries with high prevalence, such as Japan and China. In Mongolia, the incidence of CRC in the last 5 years (2018–2022) was 7.9 per 100,000 population, and the mortality rate was 4.7 per 100,000 [4].

Scientists have identified multiple risk factors for CRC. As reported in twin and family studies, hereditary factors account for approximately 12% – 35% of CRC cases [5,6]. Given this relatively low rate, it underscores the importance of other modifiable and non-modifiable risk factors. Alcohol consumption [7], smoking [8], obesity [9], unhealthy dietary patterns [10], a sedentary lifestyle [11], and psychological stress [12] are considered changeable risk factors. On the other hand, unchangeable risk factors consist of age, sex [13], genetic predisposition [14], abdominopelvic radiation exposure [15], family history of colorectal cancer [16], and a personal history of other diseases [17]. The role of the microbiome in the development and progression of CRC is increasingly recognized and appreciated as a modifiable risk factor [18].

Researchers’ interest in CRC development has shifted toward the gastrointestinal microbiome, a densely populated ecosystem. This system comprises approximately \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$10^{13}-10^{14}$\end{document}1013−1014 microorganisms in the gastrointestinal (GI) tract [19]. This microbial community is predominantly composed of Firmicutes and Bacteroidetes, which together account for about 90% of the total bacterial population [20]. Currently, researchers have identified two types of bacteria linked to colon carcinogenesis: “driver” bacteria, such as Enterococcus faecalis, Escherichia coli, and Bacteroides fragilis [21] and “passenger” bacteria, including Fusobacterium spp. and Streptococcus gallolyticus [22].

The latest meta-analysis on the association between \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli and CRC development suggests that individuals with \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli have a greater risk of developing CRC [23]. However, the role of \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli in cancer initiation, proliferation, and metastasis remains unclear. Moreover, several confounding factors influence both \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli and CRC development. The individual-specific gut microbiome is an outcome of the complex interplay between host genetics and environmental exposures [24]. As stated in a prospective cohort study, people exposed to a Western diet are more likely to develop CRCs with abundant \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli.

To summarize, substantial evidence indicates that the \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli is associated with the development of CRC. Therefore, developing a well-defined mechanistic model of \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli-mediated CRC development can inform CRC screening and characterization of CRC progression as a biomarker, enabling early detection and the development of targeted treatment strategies, such as microbiota modulation and immunomodulatory pathways.

 Method

This review study included English original articles addressing the relationship between CRC and \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli. Marcianne Elaine Gaab et al. published a meta-analysis study addressing the relationship between \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli and CRC. They included 12 articles published through January 2021 [23]. Therefore, related literature reporting the association between \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli and CRC was obtained from three databases: PubMed, Google Scholar, and the Cochrane Library, published between January 2021 and January 2026. We used the following keywords for our search strategy: pks, Escherichia coli, and colorectal cancer. Duplicate articles, review articles, animal studies, and papers with incomplete information, like conference proceedings and articles without full text, were excluded from the study.

E. coli strains classification

E. coli, a ubiquitous Gram-negative bacillus, inhabits the intestinal flora, especially in the caecum and the colon. Moreover, it can also serve as a pathogen, inducing a broad spectrum of diseases. Recently, E. coli has been classified into pathotypes based on their virulence factors and the diseases they predominantly cause in humans [25]. The strain of the pathogenic E. coli can be divided into two main groups: the first one is Intestinal Pathogenic Escherichia coli (IPEC), leading to GI infection; the second one is External Pathogenic Escherichia coli (ExPEC), which causes common infections outside of the GI tract [26].

 The E. coli infection prevalence and disease manifestations

We reviewed the primary classification of E. coli by pathotype, their prevalence, and disease manifestations in .

The prevalence of commensal E. coli varies by species: it is more than 90% in humans [27,28] but only 56% in wild mammals, 23% in birds, and 10% in reptiles [29]. The concentration of faces per gram in humans ranges from \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$10^{7}$\end{document}107 to \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$10^{9}$\end{document}109 colony-forming units [28]. The prevalence of E. coli varies across studies due to differences in study populations, diagnostic methods, and criteria. As stated in a review study that included original studies from 13 developing countries, the average incidence of EPEC among pediatric diarrheal episodes is 5–10% [30]. A retrospective case-control study revealed that children with EPEC infection had frequently experienced diarrhea, vomiting, abdominal pain, and fever, compared to EPEC-negative controls [31].

The review study analyzed data from 21 countries across 10 of the 14 WHO Sub-Regions, representing approximately 30% of the global population. According to the results, the global incidence of EHEC was 2.8 million cases per year, and its annual mortality was 230 deaths [32]. In terms of disease manifestations, bloody or watery diarrhea without fever was common, and it was sometimes associated with abdominal cramping. One of the significant complications of EHEC infection is definitely hemolytic uremic syndrome [25].

The incidence of EIEC varies widely across regions, as reported in numerous studies in Europe, Central and South America, the Middle East, West Africa, and Southeast Asia [33]. Infection with EIEC causes a bacillary dysentery characterized by bloody and mucous diarrhea, abdominal cramps, nausea, and fever [34].

Ibrahim A. Khalil et al. estimated the global incidence of ETEC diarrhea at 220 million cases per year among children under 5 years old [35]. In addition, it is a significant cause of travelers’ diarrhea, which is prevalent in regions such as Latin America, Africa, and South Asia [36]. As noted in the observational study, the most prevalent symptom was watery stool among almost all children and adults with ETEC infection. In addition, younger patients experienced frequent vomiting and fever compared to the older patients [37,38].

The incidence of EAEC infection, which can lead to acute or persistent watery diarrhea, is highest among children living in key endemic regions [39] and immunosuppressed individuals [40]. People with EAEC infection usually present the following symptoms: watery diarrhea and occasionally very mucoid diarrhea, nausea, anorexia, low-grade fever, borborygmi, and tenesmus [41].

Few studies have reported the incidence of DAEC infection, and rates have varied widely, with relatively low values. Among children with diarrhea, DAEC strains were isolated in 18.3% in Brazil and 3.9% in Iran [42,43]. DAEC infection has been considered a cause of diarrhea, particularly in children older than 24 months [44].

According to the narrative review, UPEC causes 75% of uncomplicated urinary tract infections (UTIs) and 65% of complicated UTIs [45]. Patients diagnosed with UTI caused by UPEC frequently experience dysuria and frequent urination because UPEC strains are more likely to damage the lower urinary tract [46].

The most common pathogens causing sepsis are Staphylococcus aureus and E. coli. Among infants with sepsis, E. coli is also the most prevalent gram-negative bacterium implicated in neonatal sepsis [47,48]. In addition, E. coli is the most frequently identified pathogen in cases of neonatal meningitis. Specifically, E. coli meningitis was 7-fold more common in preterm than term infants [49].

The prevalence of AIEC strains was 28% among patients with inflammatory bowel diseases and 29% among patients with Crohn’s disease in a recent meta-analysis [50]. It is well known that E. coli significantly contributes to dysbiosis of the local microbiota, thereby aggravating symptoms in inflammatory bowel diseases [51].

 Evidence summary of human studies

Since 2021, a total of 3624 articles related to \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli and CRC have been published in online databases. According to our eligibility criteria, we selected 13 articles for review. The majority of the selected studies employed retrospective cohort and case-control designs. Moreover, these studies usually detected the pks/clb gene cluster in E. coli using qPCR in both stool and tissue samples. We summarized the characteristics and results of the included studies in .

The prevalence of \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli across selected articles varied by study population and location, ranging from 9.4% to 54.7%. This variation depends on several factors, such as sample size, study population (cancer or healthy subjects), and the detection method of the pks/clb gene cluster in E. coli. Thevambiga Iyadorai et al. found significant differences in the presence of \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli isolates from tissue specimens of patients and controls, but not among fecal specimens [52]. It suggests that the detection of the pks/clb gene cluster in E. coli may depend on the specimen type. Moreover, the study evaluating the association between the pks/clb gene cluster in E. coli, measured in fecal immunochemical test (FIT) samples, and the detection of advanced neoplasia (AN) at colonoscopy included 5020 CRC screening participants. The prevalence of \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli in FIT samples from individuals with AN (28.6%) and controls (25.9%) was not significantly different. Authors suggest that a one-time \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+

E. coli measurement in stool is not informative of CRC risk in a screening setting [53].

All included studies evaluated the relationship between \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli and CRC incidence, comparing healthy and cancer subjects across cancer types, locations, and disease severity. A total of 9 studies evaluated this relationship, comparing healthy and CRC groups. To compare the presence of \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli between the control and CRC groups, 5 studies reported no significant difference, whereas 4 studies found a significant association between \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli and CRC. Kaixi Liu et al. calculated the accuracy of \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli in predicting CRC and found that the cut-off value was 2.25, with a sensitivity of 93.3% and a specificity of 73.3% [54].

In addition, these studies compared the presence of pks/clb gene cluster in E. coli across early- and late-onset cancers, disease stages, and tumor locations. The retrospective cohort study reported that early-onset CRC (EOCRC) patients (<50 years) were significantly less colonized with \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli than late-onset CRC (LOCRC) patients [55]. In another study, the \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli tumors with the APC: c.835-8 A>G mutation were more prevalent in EOCRC than LOCRC (9.5% versus 5.3%), with only the association in EOCRC showing statistical significance. The reason for this association in EOCRC is currently unknown and, if validated, would raise interesting questions about the mechanism in EOCRCs versus LOCRCs [56]. Kota Arima et al. found that the \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli level was associated with lower disease stage but not with tumor location [56]. Moreover, an observational cohort study including 413 patients with CRC found that a high level of \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli in tumor tissue was significantly associated with shallower tumor depth and the absence of lymph node metastasis. Also, they reported that the \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli low and negative groups were associated with shorter CRC-specific survival and shorter relapse-free survival [57].

Two studies evaluated the relationship between \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli and the mutational signature of CRC. The study, including 1697 tumor tissues, found that Mismatch Repair Deficiency (MMRd) status was not associated with the colibactin-associated mutational signature [56]. A total of 366 deep whole-genome sequencing (WGS) analyses showed that a large proportion of mutations in chromatin modifier genes in microsatellite-stable (MSS) cancers are driven by colibactin-associated mutational signature [58].

Yen Lin Chu et al. included 358 Lynch Syndrome (LS) cases and found that \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli in the initial CRC was associated with an increased risk of metachronous CRC and metachronous colorectal neoplasia when compared with CRCs without \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli [59].

Across the selected studies, there were inconsistencies in the results of a significant relationship between \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli and CRC development. Moreover, some studies reported a significant difference in the presence of \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli between early-onset and late-onset cancers, but others did not. The impact of \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli on MSS or MMRd cancers remains unknown. Tissue heterogeneity could influence this relationship. The majority of studies investigated the pks/clb gene cluster in E. coli using tissue samples because fecal samples were found to be less accurate. Therefore, researchers should conduct a prospective cohort study using both tissue and fecal samples and provide evidence of its use as a biomarker in screening programs.

 Evidence of the mechanism of how pks^+ pks+ E. coli impacts carcinogenesis Pathogenicity islands and key features of the pks/clb gene cluster in E. coli

HGT-mediated acquisition of large genomic islands, or pathogenicity islands (PAIs), is a key factor in the emergence of several E. coli pathotypes. PAIs, a small subgroup of genomic islands, play a significant role in bacterial virulence evolution by compromising virulence-associated factors and facilitating adaptive horizontal gene transfer. It is approximately 54 – 56 kb in size and may vary among different pks-positive strains [60,24]. The PAI named pks encoded colibactin, a nonribosomal peptide-polyketide secondary metabolite. The colibactin gene cluster within the pks genomic island comprises the clbA-clbS genes, which are responsible for colibactin synthesis [61,62]. These genes included nonribosomal peptide mega synthases (NRPSs; clbH, clbJ, and clbN), polyketide mega synthases (PKSs; clbC, clbI, and clbO), two hybrid NRPS-PKSs (clbB and clbK), and nine accessory and tailoring enzymes [63].

was adapted from the original photo with the author’s permission. The figure was generated using BioRender Software and published with permission.

Organization of the pks island: pks island encodes the genes required for the synthesis of colibactin. Genes coding for pks (yellow), non-ribosomal peptide synthase genes (blue), hybrid NRPS/PKS (green), and the accessory proteins (red) are shown. They are in connection with the regulator clbR and the integrase (int) (black). As stated in , clbA is a phosphopantetheinyl transferase, clbM is a transporter, and clbP is a peptidase.

The initiation of the biosynthesis of colibactin depends on the activation of pks/NRPS megasynthases (non-ribosomal peptides) by phosphopantetheinyl transferase ClbA. Once the initiation is activated, megasynthases recruit their specific monomers. The ClbN, whose substrate is asparagine, is regarded as the first enzyme involved in the synthesis. The Biosynthesis assembly then proceeds with the successful intervention of the ClbB-ClbC-ClbH-ClbI-ClbJ-ClbK enzymes, which exploit both common substrates, such as malonyl-CoA, alanine, serine, glycine, and cysteine, and uncommon substrates, such as aminocyclopropane-carboxylic acid, to produce the toxin in its pre-colibactin form. Once inactive pre-colibactin is formed, it is exported into the periplasm by ClbM, an efflux pump. The pre-colibactin is hydrolyzed following the insertion of ClbM into the inner membrane. It results in the separation of the cleavage product, or N-myristoyl-D-asparagine, and the active colibactin (ClbP).[65,66,63] Among all these genes, researchers have identified that five pks islet genes (ClbG, ClbH, ClbL, ClbM, and ClbS) are mainly activated during tumor development in an inflammation-dependent manner, as shown in a study using bacterial strains and plasmids. It suggests that various colibactin biosynthetic pathways alter the microenvironment during CRC development [67].

 The impact of pks^+ pks+ E. coli on the mechanism of CRC

The majority of CRCs are MSS, whereas the minority exhibit microsatellite instability (MSI), accounting for 15% [68]. However, these two types of CRC share many common driver genes and exhibit equivalent numbers of mutations in these genes [69]. MSI colon cancer is considered to have a much higher mutational load because of the lack of a DNA mismatch repair system [70]. It is well established that CpG deamination is the most common mutational process in the human colon, especially in MSS cancers [71]. According to the current evidence, researchers suggest that colibactin causes the formation of DNA cross-links by alkylating adenines [64,72,73]. This accumulation of DNA damage encourages the initiation and progression of CRC, leading to the transformation of normal colonic epithelial cells into malignant tumor cells [74].

We briefly integrated the current evidence on the mechanism of CRC induced by the \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli into . There were three crucial phases of CRC development: [74,75,76].

A. \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli produces a cyclomodulin called colibactin.

B. The CpG deamination signature is the most prevalent mutational process in human colon cancer and causes C>T mutations at methylated CG sites. Whereas the increasing number of in vivo studies has been determining the colibactin-attributable alterations in colorectal cancer. The WGS study reveals a distinct mutational signature caused by colibactin, as human intestinal organoids are exposed to genotoxic \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli via repeated luminal injections over 5 months. As stated in the study, colibactin promotes DNA alkylation in the intestinal epithelial cells, leading to the formation of interstrand cross-links and DNA double-strand breaks. These crosslinks could be resolved in various ways, including induction of DSBs, Nucleotide Excision Repair, or translation synthesis, which in turn may lead to various mutational outcomes [77,75].

C. This may result in the development of genomic instability and mutations in the prominent oncogenes and tumor suppressor genes. Over the years, the accumulation of DNA damage may drive both the initiation and progression of CRC, transforming normal colonic epithelial cells into malignant tumor cells . was independently created based on information reviewed in the literature. This figure was also created in BioRender Software, and the publication license was obtained.

It is well supported that \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli cause double-strand DNA breaks and genomic instability in host cells by extensive in vitro and in vivo studies. However, the exact other underlying mechanism could not be fully established to determine the impact of \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli on colon carcinogenesis, especially metastasis, and its interaction with a specific diet.

 Discussion

In our study, the exact prevalence of \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli and its significant relationship with CRC are inconsistent across the selected articles. However, the incidence of \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli was higher in cancer tissues than in healthy tissues. This pattern is consistent with other studies. As reported in the literature, the incidence of \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli was lower in healthy cohorts than in case groups: 22% in the USA [78]; 18.5% in Sweden [79,24]; and 4.35% in Malaysia [52]. Dietary differences could explain this prevalence of evidence of inconsistency. For instance, the western diet has been related to a higher incidence of colorectal cancer containing \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli [29,80]. In addition, a prospective Japanese study found that energy-adjusted intakes of cruciferous vegetables and vitamin C were significantly associated with a higher prevalence of \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli. Nevertheless, other factors, such as age, sex, and comorbidity, associated with the prevalence of \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli are unknown [81]. To our knowledge, these dietary factors are not considered traditional risk factors for colorectal cancer [82,83]. But could have a role in the presence of \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli; however, the reported findings are unstable [81]. Furthermore, more research is needed to establish evidence on the factors underlying the prevalence of \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli.

We found that \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli is more enriched in early-onset cancer than late-onset cancer. Marcos Díaz-Gay et al. found that late-onset cases showed enrichment for signatures similar to those observed in age-dependent changes in normal colorectal crypts. In contrast, colibactin-induced signatures were enriched in early-onset cancers. In addition, colibactin was associated with an earlier age of onset, an effect more evident in the distal colon and rectum [84]. Lee-six et al. found that the colibactin-related mutation signature in normal colonic crypts was most prevalent in younger children aged less than 10 years [71]. During the early life stage, our gut microbiome is still evolving, and it is considered a sensitive period to extrinsic influences. Therefore, it could interpret the association between APC: c.835-8 A>G and \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli in EOCRCs [85]. Yen Lin Chu et al. reported that colibactin-producing bacteria are less prevalent in EOCRC than in LOCRC. Therefore, this finding should be further confirmed in larger cohorts and a longitudinal study to determine how early mutagenic exposure of \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli influences later life and induces CRC [59].

 Limitation

Our review included articles published since 2021, potentially excluding earlier relevant studies. In addition, the prevalence of E. coli strains was insufficient to support a worldwide prevalence estimate. It depended on geography, age groups in the population, and detection methods. We could not clearly establish causality regarding the overreach of \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli in cancer due to a limited number of published articles. Therefore, to prove the relationship between \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli and CRC, large prospective studies in more controlled clinical settings are necessary.

 Conclusion

We evaluated the main characteristics of \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli and its impact on CRC development, and reviewed key features of pathogenic E. coli strains. Since the evolution of virulence in E. coli strains has been studied, horizontal gene transfer, which is crucial for the spread of the pks genomic island, has been shown to play a key role in this evolution. Therefore, colibactin, encoded by a pks, has been regarded as a key player in carcinogenesis, particularly in CRC. Several studies have proposed a primary underlying mechanism: colibactin promotes DNA alkylation in intestinal epithelial cells, thereby inducing DNA double-strand breaks. However, in human studies, results were inconsistent, and a large cohort study should be conducted to further enrich the current evidence. Furthermore, clinical translation, such as the use of screening or therapeutic biomarkers, requires prospective validation and standardized detection methods.

 Acknowledgments

The authors have no acknowledgements to declare.

 Institutional Review Board (IRB)

This review study did not require ethical approval.

 Large Language Model

No artificial intelligence tools or large language models were used to generate this manuscript.

 Authors Contribution

BU contributed to project administration, visualization, and conceptualization. CB contributed to methodology and writing-original draft. TS contributed to visualization and writing-original draft. GHD contributed to resources. YT contributed to data curation. TB contributed to writing-review and editing and supervision. GD contributed to visualization and resources. TL contributed to supervision. BB contributed to project administration and conceptualization.

 Data Availability

This article is a review of previously published literature and did not generate or analyze any new primary dataset. Therefore, no new data are available. The sources supporting the findings of this review are included in the reference list.

 Bray F. Ferlay J. Soerjomataram I. Siegel R. L. Torre L. A. Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 2018 68 6 394 424 10.3322/caac.21492 30207593 https://www.ncbi.nlm.nih.gov/pubmed/30207593 Globocan Global Cancer Observatory: Cancer Today Fu M. Li Y. Wang J. Incidence and Mortality of Colorectal Cancer in Asia in 2022 and Projections for 2050 J Gastroenterol Hepatol 2025 40 5 1143 1156 10.1111/jgh.16910 40018878 https://www.ncbi.nlm.nih.gov/pubmed/40018878 Tsedendorj Y. Zorigtbaatar S. Davaasuren N. E. Dondov G. Ganbat T. Lonjid T. Batsaikhan A. Tudev U. Batsaikhan B. Incidence and Mortality due to Colorectal Cancer in Mongolia, 2018-2022 Asian Pac J Cancer Prev 2024 25 7 2305 2310 10.31557/APJCP.2024.25.7.2305 39068562 PMC11480595 https://www.ncbi.nlm.nih.gov/pubmed/39068562 Lichtenstein P. Holm N. V. Verkasalo P. K. Iliadou A. Kaprio J. Koskenvuo M. Pukkala E. Skytthe A. Hemminki K. Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland N Engl J Med 2000 343 2 78 85 10.1056/NEJM200007133430201 10891514 https://www.ncbi.nlm.nih.gov/pubmed/10891514 Mucci L. A. Hjelmborg J. B. Harris J. R. Czene K. Havelick D. J. Scheike T. Graff R. E. Holst K. Moller S. Unger R. H. McIntosh C. Nuttall E. Brandt I. Penney K. L. Hartman M. Kraft P. Parmigiani G. Christensen K. Koskenvuo M. Holm N. V. Heikkila K. Pukkala E. Skytthe A. Adami H. O. Kaprio J. Nordic Twin Study of Cancer Collaboration Familial Risk and Heritability of Cancer Among Twins in Nordic Countries JAMA 2016 315 1 68 76 10.1001/jama.2015.17703 26746459 PMC5498110 https://www.ncbi.nlm.nih.gov/pubmed/26746459 McNabb S. Harrison T. A. Albanes D. Berndt S. I. Brenner H. Caan B. J. Campbell P. T. Cao Y. Chang-Claude J. Chan A. Chen Z. English D. R. Giles G. G. Giovannucci E. L. Goodman P. J. Hayes R. B. Hoffmeister M. Jacobs E. J. Joshi A. D. Larsson S. C. Le Marchand L. Li L. Lin Y. Mannisto S. Milne R. L. Nan H. Newton C. C. Ogino S. Parfrey P. S. Petersen P. S. Potter J. D. Schoen R. E. Slattery M. L. Su Y. R. Tangen C. M. Tucker T. C. Weinstein S. J. White E. Wolk A. Woods M. O. Phipps A. I. Peters U. Meta-analysis of 16 studies of the association of alcohol with colorectal cancer Int J Cancer 2020 146 3 861 873 10.1002/ijc.32377 31037736 PMC6819207 https://www.ncbi.nlm.nih.gov/pubmed/31037736 Botteri E. Borroni E. Sloan E. K. Bagnardi V. Bosetti C. Peveri G. Santucci C. Specchia C. van den Brandt P. Gallus S. Lugo A. Smoking and Colorectal Cancer Risk, Overall and by Molecular Subtypes: A Meta-Analysis Am J Gastroenterol 2020 115 12 1940 1949 10.14309/ajg.0000000000000803 32773458 https://www.ncbi.nlm.nih.gov/pubmed/32773458 Socol C. T. Chira A. Martinez-Sanchez M. A. Nunez-Sanchez M. A. Maerescu C. M. Mierlita D. Rusu A. V. Ruiz-Alcaraz A. J. Trif M. Ramos-Molina B. Leptin Signaling in Obesity and Colorectal Cancer Int J Mol Sci 2022 23 9 10.3390/ijms23094713 35563103 PMC9102849 https://www.ncbi.nlm.nih.gov/pubmed/35563103 Veettil S. K. Wong T. Y. Loo Y. S. Playdon M. C. Lai N. M. Giovannucci E. L. Chaiyakunapruk N. Role of Diet in Colorectal Cancer Incidence: Umbrella Review of Meta-analyses of Prospective Observational Studies JAMA Netw Open 2021 4 2 e2037341 10.1001/jamanetworkopen.2020.37341 33591366 PMC7887658 https://www.ncbi.nlm.nih.gov/pubmed/33591366 Morrison D. S. Parr C. L. Lam T. H. Ueshima H. Kim H. C. Jee S. H. Murakami Y. Giles G. Fang X. Barzi F. Batty G. D. Huxley R. R. Woodward M. Behavioural and metabolic risk factors for mortality from colon and rectum cancer: analysis of data from the Asia-Pacific Cohort Studies Collaboration Asian Pac J Cancer Prev 2013 14 2 1083 7 10.7314/apjcp.2013.14.2.1083 23621191 https://www.ncbi.nlm.nih.gov/pubmed/23621191 Kikuchi N. Nishiyama T. Sawada T. Wang C. Lin Y. Watanabe Y. Tamakoshi A. Kikuchi S. Perceived Stress and Colorectal Cancer Incidence: The Japan Collaborative Cohort Study Sci Rep 2017 7 40363 10.1038/srep40363 28091607 PMC5238416 https://www.ncbi.nlm.nih.gov/pubmed/28091607 Sung H. Ferlay J. Siegel R. L. Laversanne M. Soerjomataram I. Jemal A. Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries CA Cancer J Clin 2021 71 3 209 249 10.3322/caac.21660 33538338 https://www.ncbi.nlm.nih.gov/pubmed/33538338 Pearlman R. Frankel W. L. Swanson B. Zhao W. Yilmaz A. Miller K. Bacher J. Bigley C. Nelsen L. Goodfellow P. J. Goldberg R. M. Paskett E. Shields P. G. Freudenheim J. L. Stanich P. P. Lattimer I. Arnold M. Liyanarachchi S. Kalady M. Heald B. Greenwood C. Paquette I. Prues M. Draper D. J. Lindeman C. Kuebler J. P. Reynolds K. Brell J. M. Shaper A. A. Mahesh S. Buie N. Weeman K. Shine K. Haut M. Edwards J. Bastola S. Wickham K. Khanduja K. S. Zacks R. Pritchard C. C. Shirts B. H. Jacobson A. Allen B. de la Chapelle A. Hampel H. Ohio Colorectal Cancer Prevention Initiative Study Group Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer JAMA Oncol 2017 3 4 464 471 10.1001/jamaoncol.2016.5194 27978560 PMC5564179 https://www.ncbi.nlm.nih.gov/pubmed/27978560 Ho C. H. Cheng K. C. Chao C. M. Lai C. C. Chiang S. R. Chen C. M. Liao K. M. Wang J. J. Lee P. H. Hung C. M. Tai C. M. Chiu C. C. Does radiotherapy increase the risk of colorectal cancer among prostate cancer patients? A large population-based study J Cancer 2020 11 21 6204 6212 10.7150/jca.44726 33033503 PMC7532509 https://www.ncbi.nlm.nih.gov/pubmed/33033503 Taylor D. P. Burt R. W. Williams M. S. Haug P. J. Cannon-Albright L. A. Population-based family history-specific risks for colorectal cancer: a constellation approach Gastroenterology 2010 138 3 877 85 10.1053/j.gastro.2009.11.044 19932107 PMC2831153 https://www.ncbi.nlm.nih.gov/pubmed/19932107 Roshandel G. Ghasemi-Kebria F. Malekzadeh R. Colorectal Cancer: Epidemiology, Risk Factors, and Prevention Cancers (Basel) 2024 16 8 10.3390/cancers16081530 38672612 PMC11049480 https://www.ncbi.nlm.nih.gov/pubmed/38672612 Badero O. J. Meribole E. S. Omokore O. Quadri I. O. Kingdom P. Ifeanyichukwu O. C. Ogunnoiki S. O. Samuel-Ogunnoiki P. M. Adeyoola O. Osibowale B. Chima-Ogbuiyi N. Buari M. O. Umeh J. Adeyemi A. Gut Microbiota and Colorectal Cancer: Is Microbial Dysbiosis in Carcinogenesis an Emerging Risk Factor? Cureus 2026 18 1 e102283 10.7759/cureus.102283 41602516 PMC12834471 https://www.ncbi.nlm.nih.gov/pubmed/41602516 Gacesa R. Kurilshikov A. Vich Vila A. Sinha T. Klaassen M. A. Y. Bolte L. A. Andreu-Sanchez S. Chen L. Collij V. Hu S. Dekens J. A. M. Lenters V. C. Bjork J. R. Swarte J. C. Swertz M. A. Jansen B. H. Gelderloos-Arends J. Jankipersadsing S. Hofker M. Vermeulen R. C. H. Sanna S. Harmsen H. J. M. Wijmenga C. Fu J. Zhernakova A. Weersma R. K. Environmental factors shaping the gut microbiome in a Dutch population Nature 2022 604 7907 732 739 10.1038/s41586-022-04567-7 35418674 https://www.ncbi.nlm.nih.gov/pubmed/35418674 Gomaa E. Z. Human gut microbiota/microbiome in health and diseases: a review Antonie Van Leeuwenhoek 2020 113 12 2019 2040 10.1007/s10482-020-01474-7 33136284 https://www.ncbi.nlm.nih.gov/pubmed/33136284 Sobhani I. Amiot A. Le Baleur Y. Levy M. Auriault M. L. Van Nhieu J. T. Delchier J. C. Microbial dysbiosis and colon carcinogenesis: could colon cancer be considered a bacteria-related disease? Therap Adv Gastroenterol 2013 6 3 215 29 10.1177/1756283X12473674 23634186 PMC3625019 https://www.ncbi.nlm.nih.gov/pubmed/23634186 Tlaskalova-Hogenova H. Stepankova R. Hudcovic T. Tuckova L. Cukrowska B. Lodinova-Zadnikova R. Kozakova H. Rossmann P. Bartova J. Sokol D. Funda D. P. Borovska D. Rehakova Z. Sinkora J. Hofman J. Drastich P. Kokesova A. Commensal bacteria (normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases Immunol Lett 2004 93 2-3 97 108 10.1016/j.imlet.2004.02.005 15158604 https://www.ncbi.nlm.nih.gov/pubmed/15158604 Gaab M. E. Lozano P. O. Ibanez D. Manese K. D. Riego F. M. Tiongco R. E. Albano P. M. A Meta-Analysis on the Association of Colibactin-Producing pks+ Escherichia coli with the Development of Colorectal Cancer Lab Med 2023 54 1 75 82 10.1093/labmed/lmac072 35960765 https://www.ncbi.nlm.nih.gov/pubmed/35960765 Hall A. B. Tolonen A. C. Xavier R. J. Human genetic variation and the gut microbiome in disease Nat Rev Genet 2017 18 11 690 699 10.1038/nrg.2017.63 28824167 https://www.ncbi.nlm.nih.gov/pubmed/28824167 Gomes T. A. Elias W. P. Scaletsky I. C. Guth B. E. Rodrigues J. F. Piazza R. M. Ferreira L. C. Martinez M. B. Diarrheagenic Escherichia coli Braz J Microbiol 2016 47 Suppl 1 Suppl 1 3 30 10.1016/j.bjm.2016.10.015 27866935 PMC5156508 https://www.ncbi.nlm.nih.gov/pubmed/27866935 Palaniappan R. U. Zhang Y. Chiu D. Torres A. Debroy C. Whittam T. S. Chang Y. F. Differentiation of Escherichia coli pathotypes by oligonucleotide spotted array J Clin Microbiol 2006 44 4 1495 501 10.1128/JCM.44.4.1495-1501.2006 16597882 PMC1448672 https://www.ncbi.nlm.nih.gov/pubmed/16597882 Mitsuoka T. Hayakawa K. [The fecal flora in man. I. Composition of the fecal flora of various age groups] Penders J. Thijs C. Vink C. Stelma F. F. Snijders B. Kummeling I. van den Brandt P. A. Stobberingh E. E. Factors influencing the composition of the intestinal microbiota in early infancy Pediatrics 2006 118 2 511 21 10.1542/peds.2005-2824 16882802 https://www.ncbi.nlm.nih.gov/pubmed/16882802 Gordon D. M. Cowling A. The distribution and genetic structure of Escherichia coli in Australian vertebrates: host and geographic effects Microbiology (Reading) 2003 149 Pt 12 3575 3586 10.1099/mic.0.26486-0 14663089 https://www.ncbi.nlm.nih.gov/pubmed/14663089 Ochoa T. J. Barletta F. Contreras C. Mercado E. New insights into the epidemiology of enteropathogenic Escherichia coli infection Trans R Soc Trop Med Hyg 2008 102 9 852 6 10.1016/j.trstmh.2008.03.017 18455741 PMC2575077 https://www.ncbi.nlm.nih.gov/pubmed/18455741 Kralicek S. E. Sitaraman L. M. Kuprys P. V. Harrington A. T. Ramakrishna B. Osman M. Hecht G. A. Clinical Manifestations and Stool Load of Atypical Enteropathogenic Escherichia coli Infections in United States Children and Adults Gastroenterology 2022 163 5 1321 1333 10.1053/j.gastro.2022.07.064 35948108 PMC9613550 https://www.ncbi.nlm.nih.gov/pubmed/35948108 Majowicz S. E. Scallan E. Jones-Bitton A. Sargeant J. M. Stapleton J. Angulo F. J. Yeung D. H. Kirk M. D. Global incidence of human Shiga toxin-producing Escherichia coli infections and deaths: a systematic review and knowledge synthesis Foodborne Pathog Dis 2014 11 6 447 55 10.1089/fpd.2013.1704 24750096 PMC4607253 https://www.ncbi.nlm.nih.gov/pubmed/24750096 Vieira Nadia Bates Sarah J. Solberg Owen D. Ponce Karina Howsmon Rebecca Cevallos William Trueba Gabriel Riley L. E. E. Eisenberg Joseph N. S. High Prevalence of Enteroinvasive Escherichia Coli Isolated in a Remote Region of Northern Coastal Ecuador The American Journal of Tropical Medicine and Hygiene 2007 76 3 528 533 10.4269/ajtmh.2007.76.528 van den Beld M. J. Reubsaet F. A. Differentiation between Shigella, enteroinvasive Escherichia coli (EIEC) and noninvasive Escherichia coli Eur J Clin Microbiol Infect Dis 2012 31 6 899 904 10.1007/s10096-011-1395-7 21901636 https://www.ncbi.nlm.nih.gov/pubmed/21901636 Khalil I. A. Troeger C. Blacker B. F. Rao P. C. Brown A. Atherly D. E. Brewer T. G. Engmann C. M. Houpt E. R. Kang G. Kotloff K. L. Levine M. M. Luby S. P. MacLennan C. A. Pan W. K. Pavlinac P. B. Platts-Mills J. A. Qadri F. Riddle M. S. Ryan E. T. Shoultz D. A. Steele A. D. Walson J. L. Sanders J. W. Mokdad A. H. Murray C. J. L. Hay S. I. Reiner R. C., Jr. Morbidity and mortality due to shigella and enterotoxigenic Escherichia coli diarrhoea: the Global Burden of Disease Study 1990-2016 Lancet Infect Dis 2018 18 11 1229 1240 10.1016/S1473-3099(18)30475-4 30266330 PMC6202441 https://www.ncbi.nlm.nih.gov/pubmed/30266330 Shah Nipam DuPont Herbert L. Ramsey David J. Global Etiology of Travelers’ Diarrhea: Systematic Review from 1973 to the Present The American Journal of Tropical Medicine and Hygiene 2009 80 4 609 614 10.4269/ajtmh.2009.80.609 Chowdhury F. Islam M. T. Ahmmed F. Akter A. Mwebia M. B. Im J. Rickett N. Y. Mbae C. K. Aziz A. B. Ongadi B. Khanam F. Khan A. I. Firoj M. G. Rahman S. I. A. Park S. E. Haile K. Mwangi M. Ngugi B. Behute M. G. Kering K. Agampodi S. Kanungo S. Zaman K. Kariuki S. Qadri F. Clemens J. D. Epidemiological and Clinical Features of Enterotoxigenic Escherichia coli (ETEC) Diarrhea in an Urban Slum in Dhaka, Bangladesh Open Forum Infect Dis 2025 12 7 ofaf375 10.1093/ofid/ofaf375 40689249 PMC12272338 https://www.ncbi.nlm.nih.gov/pubmed/40689249 Khuntia H. K. Manna P. Barik D. K. Biswas S. Bramha P. K. Pati S. Ranjit M. Bal M. Kerketta A. S. High prevalence of enterotoxigenic Escherichia coli strains in hospitalized diarrhea patients: a preliminary study from a cholera-endemic area in India (2022) Front Microbiol 2025 16 1470783 10.3389/fmicb.2025.1470783 40535018 PMC12174433 https://www.ncbi.nlm.nih.gov/pubmed/40535018 Wanke C. A. Schorling J. B. Barrett L. J. Desouza M. A. Guerrant R. L. Potential role of adherence traits of Escherichia coli in persistent diarrhea in an urban Brazilian slum Pediatr Infect Dis J 1991 10 10 746 51 10.1097/00006454-199110000-00006 1658721 https://www.ncbi.nlm.nih.gov/pubmed/1658721 Mathewson J. J. Jiang Z. D. Zumla A. Chintu C. Luo N. Calamari S. R. Genta R. M. Steephen A. Schwartz P. DuPont H. L. HEp-2 cell-adherent Escherichia coli in patients with human immunodeficiency virus-associated diarrhea J Infect Dis 1995 171 6 1636 9 10.1093/infdis/171.6.1636 7769307 https://www.ncbi.nlm.nih.gov/pubmed/7769307 Peng Zhong Wang Xiangru Huang Jiangqing Li Bin Pathogenic Escherichia coli Molecular Medical Microbiology 2024 1065 1096 10.1016/b978-0-12-818619-0.00069-1 Abbasi Pejman Kargar Mohammad Doosti Abbas Mardaneh Jalal Ghorbani-Dalini Sadegh Dehyadegari Mohammad Ali Molecular Detection of Diffusely Adherent Escherichia coli Strains Associated with Diarrhea in Shiraz, Iran Archives of Pediatric Infectious Diseases 2016 5 2 10.5812/pedinfect.37629 Spano L. C. Sadovsky A. D. I. Segui P. N. Saick K. W. Kitagawa S. M. S. Pereira F. E. L. Fagundes-Neto U. Scaletsky I. C. A. Age-specific prevalence of diffusely adherent Escherichia coli in Brazilian children with acute diarrhoea J Med Microbiol 2008 57 Pt 3 359 363 10.1099/jmm.0.47660-0 18287300 https://www.ncbi.nlm.nih.gov/pubmed/18287300 Baqui A. H. Sack R. B. Black R. E. Haider K. Hossain A. Alim A. R. Yunus M. Chowdhury H. R. Siddique A. K. Enteropathogens associated with acute and persistent diarrhea in Bangladeshi children less than 5 years of age J Infect Dis 1992 166 4 792 6 10.1093/infdis/166.4.792 1527413 https://www.ncbi.nlm.nih.gov/pubmed/1527413 Medina M. Castillo-Pino E. An introduction to the epidemiology and burden of urinary tract infections Ther Adv Urol 2019 11 1756287219832172 10.1177/1756287219832172 31105774 PMC6502976 https://www.ncbi.nlm.nih.gov/pubmed/31105774 Terlizzi M. E. Gribaudo G. Maffei M. E. UroPathogenic Escherichia coli (UPEC) Infections: Virulence Factors, Bladder Responses, Antibiotic, and Non-antibiotic Antimicrobial Strategies Front Microbiol 2017 8 1566 10.3389/fmicb.2017.01566 28861072 PMC5559502 https://www.ncbi.nlm.nih.gov/pubmed/28861072 Glik J. Kawecki M. Gazdzik T. Nowak M. The impact of the types of microorganisms isolated from blood and wounds on the results of treatment in burn patients with sepsis Pol Przegl Chir 2012 84 1 6 16 10.2478/v10035-012-0002-7 22472489 https://www.ncbi.nlm.nih.gov/pubmed/22472489 Lee P. Sin E. Yip K. T. Ng K. A 10-Year Study of Neonatal Sepsis from Tuen Mun Hospital, Hong Kong Pathogens 2025 14 3 10.3390/pathogens14030276 40137761 PMC11945203 https://www.ncbi.nlm.nih.gov/pubmed/40137761 Wijetunge D. S. Gongati S. DebRoy C. Kim K. S. Couraud P. O. Romero I. A. Weksler B. Kariyawasam S. Characterizing the pathotype of neonatal meningitis causing Escherichia coli (NMEC) BMC Microbiol 2015 15 211 10.1186/s12866-015-0547-9 26467858 PMC4606507 https://www.ncbi.nlm.nih.gov/pubmed/26467858 Kamali Dolatabadi R. Feizi A. Halaji M. Fazeli H. Adibi P. The Prevalence of Adherent-Invasive Escherichia coli and Its Association With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis Front Med (Lausanne) 2021 8 730243 10.3389/fmed.2021.730243 34926490 PMC8678049 https://www.ncbi.nlm.nih.gov/pubmed/34926490 Kostic A. D. Xavier R. J. Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead Gastroenterology 2014 146 6 1489 99 10.1053/j.gastro.2014.02.009 24560869 PMC4034132 https://www.ncbi.nlm.nih.gov/pubmed/24560869 Iyadorai T. Mariappan V. Vellasamy K. M. Wanyiri J. W. Roslani A. C. Lee G. K. Sears C. Vadivelu J. Prevalence and association of pks+ Escherichia coli with colorectal cancer in patients at the University Malaya Medical Centre, Malaysia PLoS One 2020 15 1 e0228217 10.1371/journal.pone.0228217 31990962 PMC6986756 https://www.ncbi.nlm.nih.gov/pubmed/31990962 de Klaver W. de Wit M. Bolijn A. Tijssen M. Delis-van Diemen P. Lemmens M. Spaander M. C. Dekker E. van Leerdam M. E. Coupe V. M. van Boxtel R. Clevers H. Carvalho B. Meijer G. A. Polyketide synthase positive Escherichia coli one-time measurement in stool is not informative of colorectal cancer risk in a screening setting J Pathol 2024 263 2 217 225 10.1002/path.6276 38551073 https://www.ncbi.nlm.nih.gov/pubmed/38551073 Liu K. Yang X. Zeng M. Yuan Y. Sun J. He P. Sun J. Xie Q. Chang X. Zhang S. Chen X. Cai L. Xie Y. Jiao X. The Role of Fecal Fusobacterium nucleatum and pks(+) Escherichia coli as Early Diagnostic Markers of Colorectal Cancer Dis Markers 2021 2021 1171239 10.1155/2021/1171239 34853619 PMC8629656 https://www.ncbi.nlm.nih.gov/pubmed/34853619 Oliero M. Hajjar R. Cuisiniere T. Fragoso G. Calve A. Dagbert F. Loungnarath R. Sebajang H. Schwenter F. Wassef R. Ratelle R. De Broux E. Richard C. S. Santos M. M. Prevalence of pks + bacteria and enterotoxigenic Bacteroides fragilis in patients with colorectal cancer Gut Pathog 2022 14 1 51 10.1186/s13099-022-00523-y 36578036 PMC9798702 https://www.ncbi.nlm.nih.gov/pubmed/36578036 Joo J. E. Chu Y. L. Georgeson P. Walker R. Mahmood K. Clendenning M. Meyers A. L. Como J. Joseland S. Preston S. G. Diepenhorst N. Toner J. Ingle D. J. Sherry N. L. Metz A. Lynch B. M. Milne R. L. Southey M. C. Hopper J. L. Win A. K. Macrae F. A. Winship I. M. Rosty C. Jenkins M. A. Buchanan D. D. Intratumoral presence of the genotoxic gut bacteria pks(+) E. coli, Enterotoxigenic Bacteroides fragilis, and Fusobacterium nucleatum and their association with clinicopathological and molecular features of colorectal cancer Br J Cancer 2024 130 5 728 740 10.1038/s41416-023-02554-x 38200234 PMC10912205 https://www.ncbi.nlm.nih.gov/pubmed/38200234 Miyasaka T. Yamada T. Uehara K. Sonoda H. Matsuda A. Shinji S. Ohta R. Kuriyama S. Yokoyama Y. Takahashi G. Iwai T. Takeda K. Ueda K. Kanaka S. Ohashi R. Yoshida H. Pks-positive Escherichia coli in tumor tissue and surrounding normal mucosal tissue of colorectal cancer patients Cancer Sci 2024 115 4 1184 1195 10.1111/cas.16088 38297479 PMC11007018 https://www.ncbi.nlm.nih.gov/pubmed/38297479 Chen B. Ramazzotti D. Heide T. Spiteri I. Fernandez-Mateos J. James C. Magnani L. Graham T. A. Sottoriva A. Contribution of pks(+) E. coli mutations to colorectal carcinogenesis Nat Commun 2023 14 1 7827 10.1038/s41467-023-43329-5 38030613 PMC10687070 https://www.ncbi.nlm.nih.gov/pubmed/38030613 Chu Y. L. Georgeson P. Clendenning M. Mahmood K. Walker R. Como J. Joseland S. Preston S. G. Rice T. Lynch B. M. Milne R. L. Southey M. C. Giles G. G. Phipps A. I. Hopper J. L. Win A. K. Rosty C. Macrae F. A. Winship I. Jenkins M. A. Buchanan D. D. Joo J. E. Intratumoural pks(+)Escherichia coli is associated with risk of metachronous colorectal cancer and adenoma development in people with Lynch syndrome EBioMedicine 2025 114 105661 10.1016/j.ebiom.2025.105661 40158390 PMC11995779 https://www.ncbi.nlm.nih.gov/pubmed/40158390 Groisman E. A. Ochman H. Pathogenicity islands: bacterial evolution in quantum leaps Cell 1996 87 5 791 4 10.1016/s0092-8674(00)81985-6 8945505 https://www.ncbi.nlm.nih.gov/pubmed/8945505 Addington E. Sandalli S. Roe A. J. Current understandings of colibactin regulation Microbiology (Reading) 2024 170 2 10.1099/mic.0.001427 38314762 PMC10924459 https://www.ncbi.nlm.nih.gov/pubmed/38314762 Putze J. Hennequin C. Nougayrede J. P. Zhang W. Homburg S. Karch H. Bringer M. A. Fayolle C. Carniel E. Rabsch W. Oelschlaeger T. A. Oswald E. Forestier C. Hacker J. Dobrindt U. Genetic structure and distribution of the colibactin genomic island among members of the family Enterobacteriaceae Infect Immun 2009 77 11 4696 703 10.1128/IAI.00522-09 19720753 PMC2772509 https://www.ncbi.nlm.nih.gov/pubmed/19720753 Sadeghi M. Mestivier D. Sobhani I. Contribution of pks+ Escherichia coli (E. coli) to Colon Carcinogenesis Microorganisms 2024 12 6 10.3390/microorganisms12061111 38930493 PMC11205849 https://www.ncbi.nlm.nih.gov/pubmed/38930493 Nougayrede J. P. Homburg S. Taieb F. Boury M. Brzuszkiewicz E. Gottschalk G. Buchrieser C. Hacker J. Dobrindt U. Oswald E. Escherichia coli induces DNA double-strand breaks in eukaryotic cells Science 2006 313 5788 848 51 10.1126/science.1127059 16902142 https://www.ncbi.nlm.nih.gov/pubmed/16902142 Bian X. Plaza A. Zhang Y. Muller R. Two more pieces of the colibactin genotoxin puzzle from Escherichia coli show incorporation of an unusual 1-aminocyclopropanecarboxylic acid moiety Chem Sci 2015 6 5 3154 3160 10.1039/c5sc00101c 28706687 PMC5490422 https://www.ncbi.nlm.nih.gov/pubmed/28706687 Mousa J. J. Yang Y. Tomkovich S. Shima A. Newsome R. C. Tripathi P. Oswald E. Bruner S. D. Jobin C. MATE transport of the E. coli-derived genotoxin colibactin Nat Microbiol 2016 1 15009 10.1038/nmicrobiol.2015.9 27571755 PMC5704960 https://www.ncbi.nlm.nih.gov/pubmed/27571755 Tang-Fichaux M. Chagneau C. V. Bossuet-Greif N. Nougayrede J. P. Oswald E. Branchu P. The Polyphosphate Kinase of Escherichia coli Is Required for Full Production of the Genotoxin Colibactin mSphere 2020 5 6 10.1128/mSphere.01195-20 33328353 PMC7771237 https://www.ncbi.nlm.nih.gov/pubmed/33328353 Pino M. S. Chung D. C. The chromosomal instability pathway in colon cancer Gastroenterology 2010 138 6 2059 72 10.1053/j.gastro.2009.12.065 20420946 PMC4243705 https://www.ncbi.nlm.nih.gov/pubmed/20420946 Martincorena I. Raine K. M. Gerstung M. Dawson K. J. Haase K. Van Loo P. Davies H. Stratton M. R. Campbell P. J. Universal Patterns of Selection in Cancer and Somatic Tissues Cell 2017 171 5 1029 1041 e21 10.1016/j.cell.2017.09.042 29056346 PMC5720395 https://www.ncbi.nlm.nih.gov/pubmed/29056346 Vogelstein B. Papadopoulos N. Velculescu V. E. Zhou S. Diaz L. A., Jr. Kinzler K. W. Cancer genome landscapes Science 2013 339 6127 1546 58 10.1126/science.1235122 23539594 PMC3749880 https://www.ncbi.nlm.nih.gov/pubmed/23539594 Lee-Six H. Olafsson S. Ellis P. Osborne R. J. Sanders M. A. Moore L. Georgakopoulos N. Torrente F. Noorani A. Goddard M. Robinson P. Coorens T. H. H. O'Neill L. Alder C. Wang J. Fitzgerald R. C. Zilbauer M. Coleman N. Saeb-Parsy K. Martincorena I. Campbell P. J. Stratton M. R. The landscape of somatic mutation in normal colorectal epithelial cells Nature 2019 574 7779 532 537 10.1038/s41586-019-1672-7 31645730 https://www.ncbi.nlm.nih.gov/pubmed/31645730 Wirbel J. Pyl P. T. Kartal E. Zych K. Kashani A. Milanese A. Fleck J. S. Voigt A. Y. Palleja A. Ponnudurai R. Sunagawa S. Coelho L. P. Schrotz-King P. Vogtmann E. Habermann N. Nimeus E. Thomas A. M. Manghi P. Gandini S. Serrano D. Mizutani S. Shiroma H. Shiba S. Shibata T. Yachida S. Yamada T. Waldron L. Naccarati A. Segata N. Sinha R. Ulrich C. M. Brenner H. Arumugam M. Bork P. Zeller G. Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer Nat Med 2019 25 4 679 689 10.1038/s41591-019-0406-6 30936547 PMC7984229 https://www.ncbi.nlm.nih.gov/pubmed/30936547 Xue M. Kim C. S. Healy A. R. Wernke K. M. Wang Z. Frischling M. C. Shine E. E. Wang W. Herzon S. B. Crawford J. M. Structure elucidation of colibactin and its DNA cross-links Science 2019 365 6457 10.1126/science.aax2685 31395743 PMC6820679 https://www.ncbi.nlm.nih.gov/pubmed/31395743 Cuevas-Ramos G. Petit C. R. Marcq I. Boury M. Oswald E. Nougayrede J. P. Escherichia coli induces DNA damage in vivo and triggers genomic instability in mammalian cells Proc Natl Acad Sci U S A 2010 107 25 11537 42 10.1073/pnas.1001261107 20534522 PMC2895108 https://www.ncbi.nlm.nih.gov/pubmed/20534522 Pleguezuelos-Manzano C. Puschhof J. Rosendahl Huber A. van Hoeck A. Wood H. M. Nomburg J. Gurjao C. Manders F. Dalmasso G. Stege P. B. Paganelli F. L. Geurts M. H. Beumer J. Mizutani T. Miao Y. van der Linden R. van der Elst S. Genomics England Research Consortium Garcia K. C. Top J. Willems R. J. L. Giannakis M. Bonnet R. Quirke P. Meyerson M. Cuppen E. van Boxtel R. Clevers H. Mutational signature in colorectal cancer caused by genotoxic pks(+) E. coli Nature 2020 580 7802 269 273 10.1038/s41586-020-2080-8 32106218 PMC8142898 https://www.ncbi.nlm.nih.gov/pubmed/32106218 Rosendahl Huber A. Pleguezuelos-Manzano C. Puschhof J. Ubels J. Boot C. Saftien A. Verheul M. Trabut L. T. Groenen N. van Roosmalen M. Ouyang K. S. Wood H. Quirke P. Meijer G. Cuppen E. Clevers H. van Boxtel R. Improved detection of colibactin-induced mutations by genotoxic E. coli in organoids and colorectal cancer Cancer Cell 2024 42 3 487 496 e6 10.1016/j.ccell.2024.02.009 38471458 https://www.ncbi.nlm.nih.gov/pubmed/38471458 Dougherty M. W. Jobin C. Shining a Light on Colibactin Biology Toxins (Basel) 2021 13 5 10.3390/toxins13050346 34065799 PMC8151066 https://www.ncbi.nlm.nih.gov/pubmed/34065799 Dejea C. M. Fathi P. Craig J. M. Boleij A. Taddese R. Geis A. L. Wu X. DeStefano Shields C. E. Hechenbleikner E. M. Huso D. L. Anders R. A. Giardiello F. M. Wick E. C. Wang H. Wu S. Pardoll D. M. Housseau F. Sears C. L. Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria Science 2018 359 6375 592 597 10.1126/science.aah3648 29420293 PMC5881113 https://www.ncbi.nlm.nih.gov/pubmed/29420293 Eklof V. Lofgren-Burstrom A. Zingmark C. Edin S. Larsson P. Karling P. Alexeyev O. Rutegard J. Wikberg M. L. Palmqvist R. Cancer-associated fecal microbial markers in colorectal cancer detection Int J Cancer 2017 141 12 2528 2536 10.1002/ijc.31011 28833079 PMC5697688 https://www.ncbi.nlm.nih.gov/pubmed/28833079 Arima K. Zhong R. Ugai T. Zhao M. Haruki K. Akimoto N. Lau M. C. Okadome K. Mehta R. S. Vayrynen J. P. Kishikawa J. Twombly T. S. Shi S. Fujiyoshi K. Kosumi K. Ogata Y. Baba H. Wang F. Wu K. Song M. Zhang X. Fuchs C. S. Sears C. L. Willett W. C. Giovannucci E. L. Meyerhardt J. A. Garrett W. S. Huttenhower C. Chan A. T. Nowak J. A. Giannakis M. Ogino S. Western-Style Diet, pks Island-Carrying Escherichia coli, and Colorectal Cancer: Analyses From Two Large Prospective Cohort Studies Gastroenterology 2022 163 4 862 874 10.1053/j.gastro.2022.06.054 35760086 PMC9509428 https://www.ncbi.nlm.nih.gov/pubmed/35760086 Iwasaki M. Kanehara R. Yamaji T. Katagiri R. Mutoh M. Tsunematsu Y. Sato M. Watanabe K. Hosomi K. Kakugawa Y. Ikematsu H. Hotta K. Kunisawa J. Wakabayashi K. Matsuda T. Association of Escherichia coli containing polyketide synthase in the gut microbiota with colorectal neoplasia in Japan Cancer Sci 2022 113 1 277 286 10.1111/cas.15196 34779109 PMC8748232 https://www.ncbi.nlm.nih.gov/pubmed/34779109 Keum N. Giovannucci E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies Nat Rev Gastroenterol Hepatol 2019 16 12 713 732 10.1038/s41575-019-0189-8 31455888 https://www.ncbi.nlm.nih.gov/pubmed/31455888 Song M. Garrett W. S. Chan A. T. Nutrients, foods, and colorectal cancer prevention Gastroenterology 2015 148 6 1244 60 e16 10.1053/j.gastro.2014.12.035 25575572 PMC4409470 https://www.ncbi.nlm.nih.gov/pubmed/25575572 Diaz-Gay M. Dos Santos W. Moody S. Kazachkova M. Abbasi A. Steele C. D. Vangara R. Senkin S. Wang J. Fitzgerald S. Bergstrom E. N. Khandekar A. Otlu B. Abedi-Ardekani B. de Carvalho A. C. Cattiaux T. Penha R. C. C. Gaborieau V. Chopard P. Carreira C. Cheema S. Latimer C. Teague J. W. Mukeriya A. Zaridze D. Cox R. Albert M. Phouthavongsy L. Gallinger S. Malekzadeh R. Niavarani A. Miladinov M. Eric K. Milosavljevic S. Sangrajrang S. Curado M. P. Aguiar S. Reis R. M. Reis M. T. Romagnolo L. G. Guimaraes D. P. Holcatova I. Kalvach J. Vaccaro C. A. Pinero T. A. Swiatkowska B. Lissowska J. Roszkowska-Purska K. Huertas-Salgado A. Shibata T. Shiba S. Sangkhathat S. Chitapanarux T. Roshandel G. Ashton-Prolla P. Damin D. C. de Oliveira F. H. Humphreys L. Lawley T. D. Perdomo S. Stratton M. R. Brennan P. Alexandrov L. B. Geographic and age variations in mutational processes in colorectal cancer Nature 2025 643 8070 230 240 10.1038/s41586-025-09025-8 40267983 PMC12221974 https://www.ncbi.nlm.nih.gov/pubmed/40267983 Arrieta M. C. Stiemsma L. T. Amenyogbe N. Brown E. M. Finlay B. The intestinal microbiome in early life: health and disease Front Immunol 2014 5 427 10.3389/fimmu.2014.00427 25250028 PMC4155789 https://www.ncbi.nlm.nih.gov/pubmed/25250028

Organization of \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ island (Modified figure based on Nougayrède et al.’s (2006) [64] illustrations)

A general illustration of CRC development by induction of \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ Escherichia coli.

Classification of commensal and pathogenic E. coli

Group Pathotype Prevalence Symptoms Reference
Commensal E. coli Normal flora; widespread in the gut No symptoms [29,27,28]
Pathogenic E. coli IPEC (Intestinal Pathogenic Escherichia coli) Enteropathogenic E. coli (EPEC) 5-10% of pediatric diarrheal episodes in the developing world Diarrhea, vomiting, fever, and severe abdominal pain [31,30]
Enterohemorrhagic E. coli (EHEC) 2.8 million cases per year, globally Bloody or watery diarrhea without fever, abdominal cramps, dehydration, asthenia, decreased urine output, and hemolytic uremic syndrome [25]
Enteroinvasive E. coli (EIEC) Substantial regional heterogeneity Abdominal cramps, nausea, fever, and bloody and mucus diarrhea [34,33]
Enterotoxigenic E. coli (ETEC) 220 million cases annually, with 84.4 million cases reported in children aged \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$<5$\end{document}<5 years; most prevalent among travelers Watery diarrhea, severe dehydration, vomiting, and fever, especially in children [37,35,38,36]
Enteroaggregative E. coli (EAEC) Children, HIV patients Watery diarrhea, occasionally very mucoid diarrhea, nausea, anorexia, low-grade fever, borborygmi, and tenesmus [40,41,39]
Diffusely adherent E. coli (DAEC) Higher rates in children in both developing and developed countries Persistent diarrhea [42,44,43]
ExPEC(Extraintestinal Pathogenic Escherichia coli) Urophatogenic E. coli (UPEC) 75% of uncomplicated UTI cases Dysuria, frequency, fever [45,46]
Sepsis-associated E. coli (SEPEC) The most prevalent bacteria in sepsis cases Severe fever, chills, tachycardia, hypotension, and multiple-organ dysfunction syndrome [47,48]
Meningitis-associated E. coli (MNEC) The most frequently identified agent, especially in preterm neonates Meningitis symptoms [49]
Adherent-invasive E. coli (AIEC) \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$\sim 28$\end{document}~28% among IBD and CD patients Dysbiosis [50,51]

The prevalence information is approximate, depending on the study population, age groups, and method. HIV, Human Immunodeficiency Virus; UTI, Urinary Tract Infection; IBD, Inflammatory Bowel Disease; CD, Crohn’s Disease.

Summary of studies evaluating the prevalence and clinical significance of \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli in colorectal cancer

Author, year Study subject Specimen type and detection method Prevalence of \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document} p k s + E. coli Main outcome (relationship between \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document} p k s + E. coli and CRC)
Yen Lin Chu et al., 2025 A total of 358 LS cases, including 386 CRCs, 90 adenomas, and 195 normal subjects. Tissue sample; qPCR The prevalence was 13.6%. \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli was enriched in LS CRCs when compared with sporadic CRCs (OR = 1.60; 95% CI = 1.08–2.35). \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli in the initial CRC was associated with an increased risk of metachronous CRC (HR = 2.32; 95% CI = 1.29–4.17) and metachronous colorectal neoplasia (HR = 1.51; 95% CI = 1.02–2.23).
Toshimitsu Miyasaka et al., 2024 413 patients with CRC Both tumor and normal tissue; droplet digital PCR The prevalence was 65.6% (271) in tumor tissues and 62.3% (152) in normal tissues. High level of \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli in tumor tissue was significantly associated with shallower tumor depth (HR = 5.0, 95% CI = 2.3–11.3) and absence of lymph node metastasis (HR = 3.0, 95% CI = 1.8–5.1). \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli-low and -negative groups were associated with shorter CRC-specific survival (HR = 6.4, 95% CI = 1.7–25.6) and shorter relapse-free survival (HR = 3.1, 95% CI = 1.3–7.3).
Jihoon E. Joo et al., 2024 1697 tumor tissues from 1666 individuals with CRC Tumor tissue; qPCR Intratumoral prevalence of \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli was 10.3% (174). The APC: c.835-8 A\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$>$\end{document}>G mutation was associated with intratumoral \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli (P = 0.025, OR = 2.20, 95% CI = 1.05–4.25). MMRd status was not associated with \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli.
Willemijn de Klaver et al., 2024 5020 CRC screening patients Stool sample; qPCR 1322 (26.2%) were \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli positive: 28.6% in AN and 25.9% in controls. There was no significant difference between the prevalence of \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli in individuals with AN and controls (p = 0.131).
Xiaoming He et al., 2024 100 participants (50 colorectal cancer patients and 50 healthy controls) Both stool and tissue samples; qPCR The prevalence was 35%: 46% (23) in the control group and 24% (12) in the CRC group. A higher proportion of \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli was found in late-onset CRC (17 out of 35) compared to early-onset CRC (3 out of 35; P \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$<$\end{document}< 0.05).
Bingjie Chen et al., 2023 366 deep WGS samples: 101 normal samples (74 adjacent and 27 distant normal crypts) and 265 cancer samples. Both healthy and tumor tissue; WGS The prevalence was 76.67% in cancer crypts, 70.59% in adjacent normal, and 50% in distant normal from cancer patients, compared to 30% in individuals without cancer. The \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ signature causes a large proportion of mutations in chromatin modifier genes in MSS cancers. Multiple alterations in cancer driver genes and chromatin modifier genes are consistent with \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+-induced short T-dels.
Thevambiga Iyadorai et al., 2023 57 specimens (31 CRC tissue and 26 healthy normal tissue) Both fecal and tissue samples; PCR Among 37 fecal specimens, 43.6% had the pks gene [61% (13) from CRC and 31.3% (5) from control]. Among 20 tissue samples, 55.0% (11) had pks, including 80.0% (8) from CRC patients and 30.0% (3) from healthy controls. Significant differences in the presence of pks among E. coli isolates from tissue specimens of patients and controls were observed, but not among those from fecal specimens.
Kota Arima et al., 2022 1175 patients with CRC Tumor tissue; qPCR The prevalence was 9.4% (11). The \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli level was associated with lower disease stage (P = 0.008) but not with tumor location, microsatellite instability, or BRAF, KRAS, or PIK3CA mutations (P \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$>$\end{document}> 0.05).
Habiba Tariq et al., 2022 60 patients (35 patients with CRC and 25 relatively healthy patients) Both tumor and healthy tissue; quadruplex PCR The prevalence was 18.3% (11 in the CRC group and none in the healthy group). A significant association between the genotoxin-producing colibactin gene and colorectal cancer was reported (P \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$<$\end{document}< 0.002).
Manon Oliero et al., 2022 156 participants: healthy controls (N = 62) and CRC patients (N = 94) Fecal samples; conventional qualitative PCR Prevalence of \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ bacteria was 44.2% (69): 42% (26) in healthy controls and 46% (43) in the CRC group. EOCRC (\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$<$\end{document}<50 years) patients were significantly less colonized with \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli than LOCRC patients (P \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$<$\end{document}< 0.05).
Motoki Iwasaki et al., 2022 968 screening patients (543 CRC and 425 controls) Stool sample; qPCR The prevalence was 31.8% (308): 32.6% (177) in cases and 30.8% (131) in controls. No significant association was found between \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli and colorectal neoplasia (adjusted OR = 1.04, 95% CI = 0.77–1.41).
Kaixi Liu et al., 2021 139 patients with CRC and 42 healthy individuals Stool sample; qPCR method The prevalence was 54.7% (76): 21.4% (9) in control, 67.6% (25) in CAP, and 70.0% (42) in CRC cases. \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli levels were higher in the CRC group than in either the CAP group or healthy controls. No difference was found among tumor sites. The cut-off value for \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli was 2.25, with a sensitivity of 93.3% and a specificity of 73.3%.
Alfonso Piciocchi et al., 2021 330 adult subjects: 162 healthy tissues, 55 tissues with HP, 79 P/A, and 29 ADC Both healthy and cancer tissues; qPCR The prevalence was 38%: 35% (54) in healthy tissue, 42% (22) in HP, 36% (27) in P/A, and 52% (14) in ADC. There was no significant association between \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$pks^+$\end{document}pks+ E. coli and adenocarcinoma by univariate analysis (OR = 2.01, 95% CI = 0.88–4.64).

ADC, Adenocarcinomas; AN, Advanced Neoplasia; CRC, Colorectal cancer; HP, Hyperplastic Polyps; LS, Lynch Syndrome; MMRd, Mismatch Repair Deficiency; MSS, Microsatellite Stable; P/A, Pre-Cancerous Polyps/Adenomas; qPCR, Quantitative Polymerase Chain Reaction; WGS, Whole Genome Sequencing.